• Vaccine Name: WEEV Subunit E2 Protein Vaccine
• Target Pathogen: Western equine encephalomyelitis virus
• Target Disease: Western equine encephalomyelitis (WEE)
• Vaccine Ontology ID: VO_0011506
• Type: Subunit vaccine
• Status: Research
• E2 gene engineering:
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001260
• Immunization Route: Intraperitoneal injection (i.p.)

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: mice were immunized intraperitoneally with 50 μg of endotoxin-free E. coli-expressed rE2 antigen emulsified with equal volume of TiterMax Gold adjuvant. Two weeks following primary immunization, mice were immunized with the same amount of antigen emulsified with TiterMax Gold adjuvants. After the 3rd and 4th week, mice were further immunized with the same amount of antigen diluted in PBS. Control mice were immunized with only TiterMax Gold adjuvants (Das et al., 2007).
• Challenge Protocol: Live virus working stocks were prepared by diluting 1.5 × 10^3 Plaque Forming Units (PFUs) of WEEV in 50 μl HBSS and was administered to the mice intranasally. Sodium pentobarbital (50 mg/kg body weight) was used intraperitoneally to anaesthetize the mice. When the animals were unconscious, they were carefully supported by hand with their nose up and the virus suspension in HBSS gently applied with a micropipette intranasally. The applied volume was then naturally inhaled into the lungs. Infected animals were observed daily, for up to 14 days post-infection (Das et al., 2007).
• Efficacy: rE2-immunized mice were be partially protected from lethal challenge of WEEV (Das et al., 2007).